The addition of pembrolizumab was associated with a favorable trend toward improved event-free survival versus placebo plus CRT, but the difference did not reach statistical significance in the ITT population (the 24-month event-free survival rate was 63.2% for the pembrolizumab arm versus 56.2% in the placebo arm). 62 Currently, several clinical trials are exploring the role of different ICIs in LACC setting ( Table 1 ).
2
—
—
The sentences
The addition of pembrolizumab was associated with a favorable trend toward improved event-free survival versus placebo plus CRT, but the difference did not reach statistical significance in the ITT population (the 24-month event-free survival rate was 63.2% for the pembrolizumab arm versus 56.2% in the placebo arm). 62 Currently, several clinical trials are exploring the role of different ICIs in LACC setting ( Table 1 ).